All News
Late Should Not Be Less (11.3.2023)
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from the past week on RheumNow.com.
Read ArticleH. Zoster Subunit Vaccine Efficacy with JAK Inhibitor Therapy
JAK inhibitors are known to increase the risk of herpes zoster infections between between 3-5 fold. Two recent reports suggest variable efficacy when JAK inhibitor (JAKi) treated patients are vaccinated with the recombinant herpes zoster subunit vaccine (RZV).
Read ArticleOral Surveillance Study Alters Practice at VA
Safety risks found in a postmarketing trial with the Janus-associated kinase (JAK) inhibitor tofacitinib (Xeljanz) appear to have influenced prescribing patterns across the class for rheumatoid arthritis (RA) patients in the Veterans Affairs (VA) health system, researchers found.
Read ArticleCardiovascular and Venous Thromboembolic Risk With JAK Inhibitor Treatment of Skin Disorders
A JAMA systematic review and meta-analysis has showed the use of JAK inhibitors (JAKi) in immune-mediated inflammatory skin diseases was not associated with increased risk of all-cause mortality, major adverse cardiovascular events (MACE), or venous thromboembolism (VTE) (compared to the placebo
Read ArticleChoosing steroid sparing therapies in PMR
Despite the official recognition of PMR as a distinct disease more than 60 years ago, patients with PMR are still largely treated with steroids (glucocorticoids, mostly prednisone). The persistent broad use of glucocorticoids in PMR is related to their quick initial efficacy in the majority of patients with PMR, their low price and the lack of alternative treatments and paucity of glucocorticoid-sparing treatments.
Read ArticleBlinkers and the Unseen Information Gap in PMR
In my earlier blog, PMR: glad or bad tidings? I mentioned our PMR Voices 2021 public engagement project. This project brought home to me as a physician that although our expertise is essential, one unfortunate side-effect is that our very expertise can give us “blinkers”. One result of our “blinkers” is that we may fail to see the extent of the information gap between us and our patients with newly-diagnosed PMR.
Read ArticleFDA Approves Infliximab Biosimilar for Subcutaneous Use
Another infliximab biosimilar has been FDA approved, but this new version of Inflectra can be given subcutaneously for patients with inflammatory bowel disease.
Read ArticleSubcutaneous Biosimilars? (10.27.2023)
Dr. Jack Cush reviews RheumNow's top entries the PMR Campaign, news, journal reports and regulatory actions.
Read ArticleACR 2022 Guideline on Glucocorticoid-Induced Osteoporosis
The ACR has published its updated recommendations for prevention and treatment of glucocorticoid-induced osteoporosis (GIOP) for patients receiving >3 months treatment with glucocorticoids (GCs) ≥2.5 mg daily.
Read ArticleMethotrexate in OA (10.20.2023)
Dr. Jack Cush discusses the news, journal articles and regulatory actions. This week we discuss JAKne, DLE and SLE and more.
Read ArticleFDA Approves Bimekizumab for Plaque Psoriasis
UCB announced today that the US Food and Drug Administration (FDA) has approved bimekizumab-bkzx (Bimzelx)) for the treatment of moderate to severe plaque psoriasis in adults who needing systemic therapy or phototherapy.
Read Article2023 EULAR Lupus Management Recommendations
EULAR has published updated recommendations for the management of systemic lupus erythematosus (SLE) based on new evidence and expert opinion - formulationg five overarching principles and 13 recommendations.
Read Article